Dexmedetomidine (DEX) has been reported to promote tumour metastases. However the underlying mechanisms remain unclear. The purpose of this study was to investigate whether DEX promotes tumour metastasis by inducing myeloid-derived suppressor cells (MDSC) in the context of surgery. DEX was given to lung cancer patients and its effects on expansion of monocytic MDSC (M-MDSC) were studied in the context of surgery. Spontaneous tumour metastasis was induced in C57BL/6 mice and the effects of DEX on M-MDSC expansion and metastasis formation were assessed. DEX increased CD11b+CD33+HLA-DR–CD14+ M-MDSC in lung cancer patients after thoractomy. DEX-induced M-MDSC, in addition to have immunosuppressive activity, were more efficient in producing VEGF. Expansion of M-MDSC by DEX involved α2-adrenergic receptor. Using an experimental tumour metastasis mouse model, we demonstrated that the numbers of metastases on lung surface and CD11b+Ly6ChighLy6G− M-MDSC during postoperative period were enhanced in DEX-treated mice. Promotion of tumour metastasis by DEX-induced M-MDSC involved VEGF, a key factor for tumour angiogenesis. DEX induces the proliferation of M-MDSC during postoperative period in lung cancer patients and this cell population is qualified with potent proangiogenic ability. Treatment of mice with DEX expands M-MDSC and promotes tumour metastasis through the increasing production of VEGF.
Bone marrow mesenchymal stem cells (BMSC) transfer has been attempted as a therapeutic strategy in experimental lung injury and fibrosis. Reduction of neutrophilic infiltration is one of the mechanisms involved in this effect. However, the mechanisms by which BMSC modulate neutrophil remains unknown. Exposure of mice to bleomycin (BLM) resulted in significant accumulation of cells that express neutrophilic markers Gr-1HighCD11b+Ly-6GHighF4/80―CD115―CD49d―. These cells lacked immunosuppressive activity and could not be defined as myeloid-derived suppressor cells (MDSC). When BMSC were administrated to BLM-treated mice, they tuned the differentiation of Gr-1HighCD11b+ toward Gr-1LowCD11b+ cells. Gr-1LowCD11b+ cells exhibited unsegmented nuclei and expressed F4/80, Ly-6C, CD49d, and CD115 markers. These cells had potent immunosuppressive activity and thus could be defined as monocytic MDSC. As a result of such immunoregulation, BMSC mediated a decrease of pro-inflammatory products and amelioration of lung injury in BLM-treated mice. Further study using antibody array showed increased expression of macrophage colony-stimulating factor (M-CSF) in BMSC-treated mice. Accumulation of Gr-1LowCD11b+ cells in BMSC-treated mice was abrogated in M-CSF neutralizing mice. The beneficial effect of BMSC was independent of the ability of the cells to engraft in lung and in vitro coculture study of BMSC with Gr-1+CD11b+ cells showed that the induction of Gr-1LowCD11b+ cells by BMSC was independent of cell-cell contact. These results document the generation of Gr-1HighCD11b+ cells in BLM-treated mice, and suggest that BMSC tune the differentiation of Gr-1HighCD11b+ toward Gr-1LowCD11b+ cells and therefore inhibit the progression of BLM-induced lung injury.
Introduction: Myeloid CD11b+ cells are crucial mediators in post-operative and CFA-induced inflammation, but their role in pain, particularly the role of neutrophils, is still debated. This study employs single-cell RNA sequencing (scRNA-seq) to analyze CD11b+ cell composition in mice after surgery and CFA treatment and investigates the effects and mechanisms of Nicotinamide N-oxide (NAMO) on neutrophils and pain.Methods: scRNA-seq was used to analyze the transcriptomes of CD11b+ cells in murine models of post-operative and CFA-induced inflammation. Using comprehensive bioinformatics techniques, we identified distinct cell subpopulations and characterized their gene expression profiles and functional attributes. Based on these analyses, NAMO was selected to intervene in neutrophil differentiation and maturation. The role of the CXCR2 target gene and NAMO in modulating post-operative and inflammatory pain was then evaluated, exploring potential mechanisms.Results: scRNA-seq revealed a significant increase in neutrophils and a decrease in monocytes among CD11b+ cells following surgery and CFA treatment. Neutrophils comprised seven subpopulations at various differentiation stages from immature to mature. Given the high expression of CXCR2 in neutrophils, we used the CXCR2 inhibitor NAMO to suppress neutrophil differentiation and maturation, which subsequently alleviated post-operative and CFA-induced pain in mice. Proteomics analysis showed that NAMO treatment significantly reduced the expression of S100b and CaMKIIβ proteins in mouse neutrophils.Discussion: Following surgery and CFA treatment, mature neutrophils were significantly elevated. The CXCR2 antagonist NAMO alleviated post-surgical and CFA-induced pain by inhibiting neutrophil differentiation and maturation. These findings offer novel approaches for pain prevention and treatment.